Cutaquig is backed by the IgCares patient support program, designed to provide support for adults with PI at every step of their journey.

Learn More

Talk to a Nurse Advisor

Connect with an IgCares Nurse Advisor for treatment related questions or support.

Talk to a Nurse Advisor

  1. Kobayashi RH, Gupta S, Melamed I, et al. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (octanorm [cutaquig®]) in the Treatment of Patients with Primary Immunodeficiencies. Front Immunol. February 2019 | Volume 10 | Article 40.